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Abstract
Background: This study reviewed the impact of pre-operative chemoradiotherapy or post-operative chemotherapy
and/or radiotherapy on total mesorectal excision (TME) for ultralow rectal cancers that required either low anterior
resection with peranal coloanal anastomosis or abdomino-perineal resection (APR). We examined surgical
complications, local recurrence and survival.
Methods: Of the 1270 patients who underwent radical resection for rectal cancer from 1994 till 2007, 180 with
tumors within 4 cm with either peranal coloanal anastomosis or APR were analyzed. Patients were compared in
groups that had surgery only (Group A), pre-operative chemoradiotherapy (Group B), and post-operative therapy
(Group C).
Results: There were 115 males and the mean age was 65.43 years (range 30-89). APR was performed in 134
patients while 46 had a sphincter-preserving resection with peranal coloanal anastomosis. The mean follow-up
period was 52.98 months (range: 0.57 to 178.9). There were 69, 58 and 53 patients in Groups A, B, and C,
respectively. Nine patients in Group B could go on to have sphincter-saving rectal resection. The overall peri-
operative complication rate was 43.4% in Group A vs. 29.3% in Group B vs. 39.6% in Group C, respectively. The
local recurrence rate was significantly lower in Group B (8.6.9% vs. 21.7% in Group A vs. 33.9% in Group C) p < 0.05.
The 5-year cancer-specific survival rates for Group A was 49.3%, Group B was 69.9% and Group C was 38.8% (p =
0.14).
Conclusion: Pre-operative chemoradiation in low rectal cancer is not associated with a higher incidence of peri-
operative complications and its benefits may include reduction local recurrence.
Background
In rectal cancer surgery, resection of the tumor and
draining lymph nodes with adequate distal and circum-
ferential margins is the most important aim. Tumors in
the distal rectum have always been a challenge in their
management in terms of a higher local recurrence rate,
when compared to upper or mid rectal cancers [1,2].
Very distal rectal cancers, especially those involving the
anal sphincters are mostly treated surgically with an
abdomino-perineal resection (APR). In resectable rectal
adenocarcinoma, improved prognosis has been attribu-
ted to advances in surgical technique, namely total
mesorectal excision (TME), which is now the gold-stan-
dard procedure for mid and distal rectal cancer, with
local recurrence rates of less than 10 per cent [3-6].
With advances in the surgical techniques, better
understanding of disease spread, and the appropriate
use of post-operative chemo/radiotherapy, some of the
distal cancers can now be resected with restoration of
intestinal continuity, without compromising local recur-
rence rates at the same time[7,8]. APR is now reserved
only for distal rectal cancer when an anastomosis is not
possible.
Furthermore, randomized studies have shown benefits
of post-operative chemo/radiotherapy therapy over sur-
gery alone [9-11] in the presence of optimal surgery by
TME. Radiotherapy can either be given preoperatively
or postoperatively. The advantages of neoadjuvant ther-
apy over postoperative adjuvant therapy include: better
local control of disease, reduced therapeutic toxicity and
increasing the possibility of sphincter preservation
[12-16]. However, there are concerns of neoadjuvant
therapy on the early post-operative morbidity [17,18].
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The objective of this study was to examine the impact
of multimodality treatment of either pre-operative che-
moradiation or post-operative therapy on peri-operative
morbidity and the oncological outcomes of patients who
underwent TME surgery specifically for very low rectal
cancers that required either low anterior resection with
per anal coloanal anastomosis or abdomino-perineal
resection (APR) from a single specialized tertiary Asian
institution.
Methods
Patient population
From 1994 till 2007, 1270 patients underwent radical
resection for rectal cancer in the Department of Surgery,
The University of Hong Kong, Queen Mary Hospital.
Among them, 180 consecutive patients who suffered
from very low rectal adenocarcinoma with the tumor
within 4 cm from the anal verge and underwent TME
with either abdomino-perineal resection or ultra-low
anterior resection (ULAR) with hand-sewn coloanal ana-
stomosis were included in this study. Data on the
patients’ demographics, operative details, postoperative
outcome and follow-up status were collected in a pro-
spective database for colorectal malignancy. They either
underwent surgery alone (Group A), or had preoperative
chemoradiotherapy before surgery (Group B), or under-
went postoperative adjuvant therapy (Group C). Patients
with pathologies other than adenocarcinoma, those
undergoing emergency surgery, and those with previous
rectal surgery were excluded.
The management protocol was described in our pre-
vious publications [19,20]. All the patients underwent
colonoscopy with biopsy-proven adenocarcinoma of the
rectum. Pre-operative clinical staging comprised of a com-
bination of physical and per rectal examination, with var-
ious imaging modalities (Computed Tomography scan,
Magnetic Resonance Imaging, endoscopic ultrasound).
Policy of adjuvant therapy
In the early part of the study, preoperative chemoradia-
tion was only given to those with T4 disease. In patients
who underwent APR, based on the hypothesis that peri-
neal dissection could not achieve dissection along a well-
defined plane and that tumor implantation at the time of
operation was more likely as well as on the poor reported
oncological results of APR even using TME [21], post-
operative chemoradiation was offered to patients with
stage II and stage III disease in the early period. In those
patients with low anterior resection with TME, post-
operative radiation was not given during the initial period
of the study and postoperative chemotherapy was offered
to those with stage II or stage III disease.
After our analysis of the results of patients who
underwent APR and low anterior resection with hand-
sewn coloanal anastomosis [19], preoperative chemora-
diation was offered to those who had T3 disease and/or
positive lymph nodes by preoperative staging and were
designated to have APR or hand-sewn coloanal anasto-
mosis. From 2004, a combined multidisciplinary meeting
with surgeons, radiologists and clinical oncologists
decided the policy of adjuvant therapy of patients on
individual basis. Neoadjuvant treatment comprised of
long course 5-fluorouracil (5 FU) - based concurrent
chemotherapy (IV bolus) and radiation (4500-5040 Gy).
External beam radiation therapy was delivered at 180
cGy daily in either 3-or 4-field technique for 5 weeks,
followed by 540-cGy boosts. Surgery was subsequently
carried out within 4-6 weeks after completing neoadju-
vant treatment. The surgical approach of open versus
laparoscopic resection was chosen by the surgeon, based
on the experience and technical skills.
Surgical Technique
All patients underwent bowel preparation with polyethy-
lene glycol electrolyte solution the day before the opera-
tion and surgery was performed in the Lloyd-Davis
position. Prophylactic intravenous antibiotics were used
routinely at induction of general anesthesia.
Total mesorectal excision with rectal mobilization
being carried out by sharp dissection under direct vision
keeping the fascia propia of the mesorectum intact.
Operative techniques for APR and LAR have been pre-
viously described [19]. The decision for APR was made
if the tumor invaded the anal sphincters, an inadequate
distal margin, or if patient had poor sphincter function
preoperatively. In patients who were suitable for a pera-
nal coloanal anastomosis, the perineal surgeon com-
pleted the excision transanally at the dentate line via an
intersphincteric dissection, whereby the plane between
the internal and external sphincters was dissected proxi-
mally until it met with the intraperitoneal dissection.
The Lone Star retractor (Cooper-Surgical, Trumbull,
CT) was used for exposure and a hand-sewn single-layer
interrupted anastomosis was performed transanally.
Intestinal continuity is reestablished after completion of
adjuvant therapy, following clinical and radiological evi-
dence of anastomotic integrity.
All patients had fecal diversion with either a loop
ileostomy or a loop transverse colostomy if the ileum
was not suitable.
Postoperative management
Pathological staging of patients was performed accord-
ing to the postoperative pathological report by using the
standard tumor node metastasis (TNM) system (AJCC
6th Ed). Complete pathological response was defined as
the absence of viable tumor cells in the specimen. The
definition of anastomotic leakage was based on intra-
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operative findings on reoperation or in the case of con-
servatively managed patients, based on clinically directed
imaging investigations.
Follow up
Patients were followed up at 2-3 month intervals in the
first 2 years, then 4-6 months until 5 years after surgery
and yearly thereafter. History and physical examination
were performed at each follow-up visit. Digital rectal
examination was performed in all patients who had
ULAR to check for anastomotic recurrence or stricture.
Serum carcino-embryonic antigen (CEA) level was mea-
sured at each visit. Imaging and/or colonoscopy were
performed in patients in whom recurrence was sus-
pected. Local recurrence was defined as biopsy-proven
pelvic recurrence below sacral promontory or a rise in
serum CEA with positive imaging studies. Lung, liver
and biopsy-proven inguinal lymphadenopathy was con-
sidered as distant metastatic disease.
Statistical method
Proportions were compared using Chi-squared test or
Fisher exact test. Continuous variables were presented
as median (range) and were compared using Mann-
Whitney U test when appropriate. One-way ANOVA
was used to check equivalence of means of the 3 groups.
Cancer-specific survival and local recurrence were ana-
lyzed by the Kaplan-Meier method; comparison made
with log rank test. P values of less than 0.05 were con-
sidered statistically significant. Confidence intervals were
defined at 95 per cent.
Results
Over 14 years, 180 patients had very low rectal cancer
and required either per anal coloanal anastomosis or
abdomino-perineal resection. The characteristics of the
patients, operations and tumors are shown in Table 1.
There were 115 males and 65 females with a mean age
of 65.43 years (range 30-89). One hundred and of
Table 1 Patient, tumor and surgical characteristics
Characteristics Group A
(n = 69)
Group B
(n = 58)
Group C
(n = 53)
P value
Mean(range)Age (yrs) 70.6(33-88) 63.1(30-88) 61.2(37-89) NS
Gender
Male 36 35 35 NS
Female 33 23 18
Comorbidities NS
ASA status NS
1 11 9 13
2 44 43 34
3 13 6 6
4 1 0 0
Type of Surgery
APR 53 49 32 0.04
ULAR 16 9 21
Intent of Surgery NS
Curative 62 54 49
Palliative 7 4 4
Approach (Lap/Open) 16/53 12/46 10/43 NS
Median(range)Operating time(mins) 174.5(80-340) 185.3(75-420) 181.8(100-340) NS
Median(range)Blood loss intraop (mls) 601(50-3000) 842(99-4200) 654(99-2000) NS
Pathological tumor stage
1 28 8 2
2 19 28 13
3 16 16 34
4 4 1 4
Tumor differentiation NS
Poor 8 8 12
Moderate 52 38 39
Well 5 4 1
Neurovascular involvement 14 13 29 NS
ASA, American Society of Anesthesiologist, APR, abdomino-perineal resection, ULAR, ultra-low anterior resection, NS, not significant
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thirty-four of them underwent an APR while 46 had a
sphincter-preserving ultra-low anterior resection with
per anal coloanal anastomosis, combined with defunc-
tioning stomas (40 ileostomies and 6 colostomies).
Laparoscopic resection was used in 38 patients. All the
surgeries were performed electively with no incidence
of perforation or obstruction at the time of surgery.
The cohort had a mean follow-up period of 52.98
months (range: 0.57 to 178.9 months). Sixty-nine
patients underwent surgery only, while 58 patients
received pre-operative chemoradiotherapy, and 53
patients had post-operative adjuvant therapy in
addition to surgery. Nine out of the 58 patients with
preoperative chemoradiotherapy could have a sphinc-
ter-saving rectal resection. In Group C, 26 patients had
chemotherapy alone, 6 patients had just radiotherapy
and 21 patients had concomitant chemoradiotherapy
after the operation.
The 3 groups were comparable in terms of demo-
graphics, age, gender, comorbidities, as well as American
Society of Anesthesiology (ASA) score. The type of sur-
gery, approach (laparoscopic vs. open) and surgery with
curative intent were also similar.
There was no statistical difference in the operating time,
blood loss and intra-operative complications among the
patients in the three groups. Two patients in Group A had
ureteric injury while there were no significant intra-opera-
tive complications in patients of the other groups.
The overall peri-operative complication rate was 43.4%
in Group A, 29.3% in Group B and 39.6% in Group C
(Table 2). The breakdown of various complications
among the groups was not significantly different. The
complications are as follows: Cardiac complications
(commonest being atrial fibrillation, congestive cardiac
failure, and non-fatal myocardial infarction) were 10.1%
vs. 1.7% vs. 1.9% in Groups A, B, and C, respectively.
Pulmonary complications (commonest were pneumonia
and atelectasis) were 1.4% vs. 1.7% vs. 7.5%. Urological
complication rates (urinary tract infection and acute
retention of urine) were: 17.4% vs. 3.4% vs. 5.7%. As for
surgical complications: the wound infection rates were
8.7% vs. 13.8% vs. 15.1%. The anastomotic leak rate as
earlier defined was 0 vs. 22% vs. 10% respectively. The
re-operation rates (for leak, abscess or bleeding) were
10.1% vs. 5.2% vs. 3.8%. The overall 30-day mortality
was 0.56%(1 patient had small bowel gangrene from
Group A).
The oncological outcomes are shown in Table 3. The
5-year local recurrence rate was significantly lower in
Group B (8.6% vs. 21.7% in Group A vs. 33.9% in Group
C) (p = 0.012)(Fig 1). The median time to the occur-
rence of local recurrence for Group A was 53.3 months
(range 0.57 - 176.3 months), Group B was 33.78 months
(range 6.87 - 139.3 months), and Group C was 41.52
months(range 4.77 - 135.8 months). There was no sig-
nificant difference in the systemic recurrence among the
3 groups of patients.
The 5-year survival rate for Group A was 49.3%, Group
B was 69.9% and Group C was 38.8% (p = 0.14). (Fig 2)
Discussion
Total mesorectal excision (TME) has been used as stan-
dard surgical treatment for rectal cancers, contributing
significantly to lowered local recurrence rates [22,23].
Especially for distal rectal cancer, local recurrence is an
important end-point for success because it occurs with
significant frequency, is difficult to manage effectively
and causes significant morbidity. Previously, our center
has shown that TME with or without sphincter ablation
for patients with distal rectal cancer was associated with
low mortality rate and acceptable morbidity [19]. Those
patients who underwent total mesorectal excision with
double stapling anastomosis, the local recurrence rate
was 7.1%[24]. For the subgroup of patients very low rec-
tal cancers treated with wider surgery (APR) or low
anterior resection with peranal coloanal anastomosis,
the local control and survival were worse than those
with double stapling anastomosis. This leads to next
question of the role of adjuvant therapy for these
patients. Numerous randomized trials for rectal cancer
have now demonstrated the multimodality treatment
can further improve local control even after optimal
TME has been performed [25-28]. However, when to
give chemotherapy and radiotherapy is also a point for
debate [29].
Table 2 Postoperative complications
Complications Group A
n (%)
Group B
n (%)
Group C
n (%)
P
value
Cardiac 7 (10.1) 1 (1.7) 1 (1.9) NS
(0.272)
Pulmonary 1(1.4) 1 (1.7) 4 (7.5) NS
(0.140)
Urinary 12 (17.4) 2 (3.4) 3 (5.7) NS
(0.380)
Surgical
Intraoperative 2 (2.8) 0 (0) 1 (1.9)
Postoperative 1 (1.4) 2 (3.4) 0 (0) NS
(0.314)
Wound 6 (8.7) 8 (13.8) 8 (15.1) NS
(0.209)
Leak 0 (0) 2 (22) 2 (10) NS
(0.438)
Re-operation 7 (10.1) 3 (5.2) 2 (3.8) NS
(0.604)
30-day mortality 1 (1.4) 0 (0) 0 (0) NS
Overall perioperative
complication
30 (43.4) 17 (29.3) 21 (39.6) NS
NS
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Comparing preoperative against postoperative chemor-
adiation, the often cited theoretical advantages of preo-
perative therapy include a well-vascularized tumor
target which would optimize tumor response rates,
absence of adhesions and surgical changes which may
minimize the toxicity involved with small-bowel irradia-
tion. In addition, preoperative chemoradiation does
reduce local recurrence, increase resectability of rectal
cancer, improve possibility of sphincter preservation,
and improve disease-free and overall survival [30-32].
Our experience for these 180 patients with distal rectal
cancer did demonstrate that there was a significantly
reduced incidence of local recurrence when chemoradia-
tion was given preoperatively, regardless of whether an
APR or ULAR was performed.
However, few recent studies have reported concerns of
the effects of preoperative irradiation on operative time,
blood loss and post-operative complication rate, namely
perianal sepsis, delayed surgical wound healing, and ana-
stomotic dehiscence [33,34]. In our series, these con-
cerns did not appear to be significant, which is in
agreement with other studies, which have found no
increase in early postoperative complications with stan-
dard course preoperative chemoradiotherapy. Aggressive
chemoradiation has been shown not to affect QoL and
anorectal function [35].
Examining the stage of the tumors of the 3 groups, it
is noted that the majority of patients in Group A had
early stage 1 disease, and hence underwent upfront sur-
gery only. In contrast, Group C comprised of more
advanced disease, and there was understandably selec-
tion bias in decision for sending these patients for post-
operative therapy. Despite this, Group B had significant
lower local recurrence rate as well as longer 5-year
Table 3 Long-term follow up results
Recurrence Group A
n (%)
Group B
n (%)
Group C
n (%)
P value
Local Recurrence 15 (21.7) 5 (8.6) 18 (34) 0.012
Median(range) disease free(months) 53.3(0.57-176) 33.78(6.8-139) 41.5(4.7-136) NS
Systemic recurrence 14 (20.3) 13(22.4) 18(33.9) NS (0.543)
5 year cancer-specific survival rate (49.3) (69.9) (38.8) 0. 14
Figure 1 Comparison of local recurrence among the three groups. Green line = Group A Surgery alone; Yellow line = Group B: Preoperative
chemoradiation; Red line = Group C: Postoperative therapy.
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survival than Group A, which could be due to the bene-
ficial effects of preoperative therapy. However, there are
limitations to assess patients in group B, as they had
undergone preoperative therapy which would have
downstaged the tumour.
Inherent in any retrospective analysis, limitations and
bias do exist. These include difficulties in patient selec-
tion, which is a complex process especially in distal rec-
tal cancer. Moreover, the comparative study of available
data is complex because of different inclusion criteria
and chemoradiotherapy modalities used as well as the
policy of preoperative therapy during the study period
with the analysis of the data. 35 patients with stage 2/3
did not receive pre-operative chemoradiation because
they were in the pre-chemoradiation era. Although, our
series is not a randomized blinded study, but given the
standardized management, homogeneity of the groups
and the relatively long surgical practice of our team, the
results do represent a significant finding in terms of out-
comes of the various groups. This also demonstrated
how the change in the policy of adjuvant therapy could
help to improve the results of the patients.
Most recently, there is convincing and consistent evi-
dence that short-course preoperative radiotherapy is an
effective treatment for patients with operable rectal can-
cer [36]. However, it may not give yield superior survival
rates compared to conventional fractionated long course
chemoradiotherapy [37]. Randomized studies by The
Trans-Tasman Radiation Oncology Group trial (TROG
0.104) and the Stockholm III trial may provide more
answers in this aspect of the best way to give neoadju-
vant therapy.
In the modern context of laparoscopic TME, the cur-
rent data does not appear to show that pre-operative
chemoradiation treatment would jeopardize the perio-
perative results compared to open surgery[38]. However,
randomized controlled trials may be required to shed
more light in this area. Our data shows laparoscopic
surgery was carried out in equal proportions in the 3
different groups analyzed.
Conclusion
Pre-operative chemoradiation in patients with distal rec-
tal cancer treated with surgery is not associated with a
higher incidence of peri-operative complications. Its
benefits may include reduction in local recurrence.
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